1.
Jemal A, Thomas A, Murray T, Thun M.
Cancer statistics.
CA Cancer J Clin.
2002; 52: 23–47.
[PubMed]
2.
Levine A.
Acquired immunodeficiency syndrome-related lymphomas.
Blood.
1992; 80: 8–16.
[PubMed]
3.
Borisch B, Hennig I, Laeng R.
et al. Association of the subtype 2 of the Epstein-Barr Virus with T-cell non-Hodgkin's lymphoma of the midline granuloma type.
Blood.
1993; 82: 858–64.
[PubMed]
4.
Robert-Guroff M, Nakao Y, Notake K.
et al. Natural antibodies to human retrovirus HTLV in a cluster of Japanese patients with adult T-cell leukemia.
Science.
1982; 215: 975.
[PubMed]
5.
Fagioli F, Rigolin G, Cuneo A.
et al. Primary gastric lymphoma: distribution and clinical relevance of different epidemiological factors.
Haematologica.
1994; 79: 213–7.
[PubMed]
6.
Cesarman E, Chang Y, Moore P.
et al. Kaposi's sarcoma-associated herpes virus-like DNA sequences in AIDS-related body-cavity-based lymphomas.
N Engl J Med.
1995; 332: 1186–91.
[PubMed]
7.
Goodlad JR, Davidson MM, Hollowood K.
et al. Borrelia burgdorferi-associated cutaneous marginal zone lymphoma: a clinicopathological study of two cases illustrating the temporal progression of B. burgdorferi-associated B-cell proliferation in the skin.
Histopathology.
2000; 37: 501–8.
[PubMed]
8.
Saltzstein SL, Ackerman LV.
Lymphadenopathy induced by anticonvulsant drugs and mimicking chemically and pathologically malignant lymphomas.
Cancer.
1959; 12: 164.
[PubMed]
9.
Morrison H, Semenciw R, Wilkins K.
et al. Non-Hodgkin's lymphoma and agricultural practices in the prairie provinces of Canada.
Scand J Work Environ Health.
1994; 20: 42–7.
[PubMed]
10.
Boffetta P, Andersen A, Lynge E.
et al. Employment as hairdresser and risk of ovarian cancer and non-Hodgkin's lymphomas among women.
J Occup Med.
1994; 36: 61–5.
[PubMed]
11.
Hardell L, Eriksson M.
A case-control study of non-Hodgkin's lymphoma and exposure to pesticides.
Cancer.
1999; 85: 1353–60.
[PubMed]
12.
Hardell L, Eriksson M, Degerman A.
Exposure to phenoxyacetic acids, chlorophenols, or organic solvents in relation to histopathology, stage, and anatomical localization of non-Hodgkin's lymphoma.
Cancer Res.
1994; 54: 2386–9.
[PubMed]
13.
Colton T.
Herbicide exposure and cancer.
JAMA.
1986; 256: 1176.
[PubMed]
14.
Pearce NE, Sheppard RA, Smith AH, Teague CA.
Non-Hodgkin's lymphoma and farming: an expanded case-control study.
Int J Cancer.
1987; 39: 155.
[PubMed]
15.
Woods JS, Polissar L, Severson RK.
et al. Soft tissue sarcoma and non-Hodgkin's lymphoma in relation to phenooxyherbicide and chlorinated phenol exposure in western Washington.
J Natl Cancer Inst.
1987; 78: 899.
[PubMed]
16.
Persson B, Fredriksson M, Olsen K.
et al. Some occupational exposures as risk factors for malignant lymphomas.
Cancer.
1993; 72: 1773–8.
[PubMed]
17.
Beebe G, Kto H, Land C.
Studies of the mortality of A-bomb survivors: 6. Mortality and radiation dose.
Radiat Res.
1978; 75: 138.
[PubMed]
18.
List A, Greer J, Cousar J.
et al. Non-Hodgkin's lymphoma after treatment of Hodgkin's disease: association with Epstein-Barr virus.
Ann Intern Med.
1986; 105: 668.
[PubMed]
19.
Brennan N, Fennelly J, Towers R, FitzGerald M.
Sarcoidosis and lymphoma in the same patient.
Postgrad Med J.
1983; 59: 581–5.
[PubMed]
20.
Kassan S, Thomas T, Haralampos M.
Increased risk of lymphoma in Sicca Syndrome.
Ann Intern Med.
1978; 89: 888.
[PubMed]
21.
Purtilo D.
Hypothesis. Pathogenesis and phenotypes of and X-linked recessive lymphoproliferative syndrome.
Lancet.
1976; 2: 882.
[PubMed]
22.
Starzl T, Porter K, Iwatsuki S.
et al. Reversibility of lymphomas and lyphoproliferative lesions developing under cyclosporin-steroid therapy.
Lancet.
1984; 1: 583.
[PubMed]
23.
Ballerini P, Gaidano G, Gong J.
et al. Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma.
Blood.
1993; 81: 166.
[PubMed]
24.
Lukes RJ, Collins RD.
Immunologic characterization of human malignant lymphomas.
Cancer.
1974; 34: 1488–503.
[PubMed]
25.
Lennert K, Mohri N, Stein H. The histopathology of malignant lymphomas.
Br J Heme.
1975; 31(Suppl): 193–205.
26.
The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute-sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage.
Cancer.
1982; 49: 2112–35.
[PubMed]
27.
Rappaport H. Tumors of the hematopoietic system. Atlas of tumor pathology. Washington, DC. Sect 3, Fasicle 8, 1966.
28.
Harris N, Jaffe E, Stein H, et al. A revised EuropeanAmerican classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361–92.
[PubMed].
29.
Armitage J, Weisenburger D.
New approach to classifying Non-Hodgkin's lymphomas: clinical features of the major histologic subtypes.
J Clin Oncol.
1998; 16: 2780–95.
[PubMed]
30.
Harris NL, Jaffe ES, Diebold J.
et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting-Airlie House, Virginia, November 1997.
J Clin Oncol.
1999; 17: 3835–49.
[PubMed]
31.
Jaffe ES, Shevach EM, Frank MM.
et al. Nodular lymphoma-evidence for origin from follicular B lymphocytes.
N Engl J Med.
1974; 290: 813–9.
[PubMed]
32.
Anderson KC, Bates MP, Slaughenhoupt BL.
et al. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation.
Blood.
1984; 63: 1424–33.
[PubMed]
33.
Maio M, Pinto A, Carbone A.
et al. Differential expresison of CD54/intercellular adhesion molecule-1 in myeloid leukemias and in lymphoprolioferative disorders.
Blood.
1990; 76: 783–90.
[PubMed]
34.
Picker LJ, Medeiros LJ, Weiss LM.
et al. Expression of lymphocyte homing receptor antigen in non-Hodgkin's lymphoma.
Am J Pathol.
1988; 130: 496–504.
[PubMed]
35.
Flenghi L, Bigerna B, Fizzotti M.
et al. Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region.
Am J Pathol.
1996; 148: 1543–55.
[PubMed]
36.
Bekkenk MW, Postma TJ, Meijer CJ, Willemze R.
Frequency of central nervous system involvement in primary cutaneous B-cell lymphoma.
Cancer.
2000; 89: 913–9.
[PubMed]
37.
Cerroni L, Arzberger E, Putz B.
et al. Primary cutaneous follicle center cell lymphoma with follicular growth pattern.
Blood.
2000; 95: 3922–8.
[PubMed]
38.
Horning SJ, Rosenberg SA.
The natural history of initially untreated low-grade non-Hodgkin's lymphoma.
N Engl J Med.
1984; 311: 1471–508.
[PubMed]
39.
Longo D.
What's the deal with follicular lymphomas?
J Clin Oncol.
1993; 11: 202–8.
[PubMed]
40.
Armitage JO, Dick FR, Corder MP.
Diffuse histiocytic lymphoma after histologic conversion: a poor prognostic variant.
Cancer Treat Rep.
1981; 65: 413–8.
[PubMed]
41.
Bastion Y, Sebban C, Berger F.
et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients.
J Clin Oncol.
1997; 15: 1587–94.
[PubMed]
42.
Hubbard SM, Chabner BA, DeVita VT.
et al. Histologic progression in non-Hodgkin's lymphoma.
Blood.
1982; 59: 258–64.
[PubMed]
43.
Johnson P, Rohatiner A, Whelan J.
et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center.
J Clin Oncol.
1995; 13: 140–7.
[PubMed]
44.
Yuen A, Kamel O, Halpern J, Horning S.
Long-term survival after histologic transformation of low-grade follicular lymphoma.
J Clin Oncol.
1995; 13: 1726–33.
[PubMed]
45.
Anderson J, Vose J, Bierman P.
et al. Clinical features and prognosis of follicular large-cell lymphoma. A report from the Nebraska lymphoma study group.
J Clin Oncol.
1993; 11: 218–24.
[PubMed]
46.
Rodriguez J, McLaughlin P, Hagemeister F, Fayad L.
Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features.
Blood.
1999; 93: 2202–7.
[PubMed]
47.
Spertini O, Freedman AS, Belvin MP, et al. Regulation of leukocyte adhesion molecule-1 (TQ1, Leu-8) expression and shedding by normal and malignant cells. Leukemia 1991;5:300-8.
[PubMed].
48.
Hamblin TJ, Orchard JA, Gardiner A.
et al. Immunoglobulin V genes and CD38 expression in CLL.
Blood.
2000; 95: 2455–7.
[PubMed]
49.
Brezinschek HP, Foster SJ, Brezinschek RI.
et al. Analysis of the human VH gene repertoire. Differential effects of selection and somatic hypermutation on human peripheral CD5(+)/IgM+ and CD5(-)/IgM+ B cells.
J Clin Invest.
1997; 99: 2488–501.
[PubMed]
[
Free Full text in PMC]
50.
Oscier DG, Thompsett A, Zhu D, Stevenson FK.
Differential rates of somatic hypermutation in V(H) genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities.
Blood.
1997; 89: 4153–60.
[PubMed]
51.
Klein U, Tu Y, Stolovitzky GA.
et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells.
J Exp Med.
2001; 194: 1625–38.
[PubMed]
52.
Robertson L, Pugh W, O'Brien S.
et al. Richter's syndrome: a report on 39 patients.
J Clin Oncol.
1993; 11: 1985–9.
[PubMed]
53.
Ben-Ezra J, Burke JS, Swartz WG.
et al. Small lymphocytic lymphoma: a clinicophathologic analysis of 268 cases.
Blood.
1989; 73: 579–87.
[PubMed]
54.
Pangalis G, Angelopoulou M, Vassilakopoulos T.
et al. B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenstrom's macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders.
Semin Hematol.
1999; 36: 104–14.
[PubMed]
55.
Pozzato G, Mazzaro C, Crovatto M.
et al. Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia.
Blood.
1994; 84: 3047–53.
[PubMed]
56.
Mazzaro C, Franzin F, Tulissi P.
et al. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy.
Cancer.
1996; 77: 2604–13.
[PubMed]
57.
The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma.
Blood.
1997; 89: 3909–18.
[PubMed]
58.
Nathwani B, Drachenberg M, Hernandez A.
et al. Nodal monocytoid B-cell lymphoma (nodal marginal-zone B-cell lymphoma).
Semin Hematol.
1999; 36: 128–38.
[PubMed]
59.
Isaacson P.
Mucosa-associated lymphoid tissue lymphoma.
Semin Hematol.
1999; 36: 139–47.
[PubMed]
60.
Catovsky D, Matutes E.
Splenic lymphoma with circulating villous lymphocytes/splenic marginal-zone lymphoma.
Semin Hematol.
1999; 36: 148–54.
[PubMed]
61.
Matutes E, Morilla R, Owusu-Ankomah K.
et al. The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders.
Blood.
1994; 83: 1558–62.
[PubMed]
62.
Isaacson PG, Matutes E, Burke M, Catovsky D.
The histopathology of splenic lymphoma with villous lymphocytes.
Blood.
1994; 84: 3828–34.
[PubMed]
63.
Isaacson P, Wright D.
Malignant lymphoma of mucosal associated lymphoid tissue. A distinct B cell lymphoma.
Cancer.
1983; 52: 1410.
[PubMed]
64.
Zucca E, Bertoni F, Roggero E, Cavalli F.
The gastric marginal zone B-cell lymphoma of MALT type.
Blood.
2000; 96: 410–9.
[PubMed]
65.
Thieblemont C, Berger F, Dumontet C.
et al. Mucosaassociated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed.
Blood.
2000; 95: 802–6.
[PubMed]
66.
Traweek ST, Sheibani K, Winberg CD.
et al. Monocytoid B-cell lymphoma: its evolution and relationship to other low-grade B-cell neoplasms.
Blood.
1989; 73: 573–8.
[PubMed]
67.
Thieblemont C, Bastion Y, Berger F.
et al. Mucosa-associated lymphoid tissue gastrointestinal and non-gastrointestinal lymphoma behavior: analysis of 108 patients.
J Clin Oncol.
1997; 15: 1624–30.
[PubMed]
68.
Coiffier B, Thieblemont C, Felman P.
et al. Indolent nonfollicualr lymphomas: characteristics, treatment, and outcome.
Semin Hematol.
1999; 36: 198–208.
[PubMed]
69.
Radaszkiewicz T, Dragosics B, Bauer P.
Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis.
Gastroenterology.
1992; 102: 1628–38.
[PubMed]
70.
Hsu C, Chen CL, Chen LT.
et al. Comparison of MALT and non-MALT primary large cell lymphoma of the stomach. Does histologic evidence of MALT affect chemotherapy response?
Cancer.
2001; 91: 49–56.
[PubMed]
71.
Fisher R, Dahlberg S, Nathwani B.
et al. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including mucosal-associated lymphoid tissue and monocytoid B-cell subcatagories). A Southwest Oncology Group Study.
Blood.
1995; 85: 1075–82.
[PubMed]
72.
Shivdasani R, Hess J, Skarin A, Pinkus G.
Intermediate lymphocytic lymphoma: clinical and pathologic features of a recently characterized subtype of non-Hodgkin's lymphoma [see comments].
J Clin Oncol.
1993; 11: 802–11.
[PubMed]
73.
Weisenburger DD, Sanger WG, Armitage JO, Purtilo DT.
Intermediate lymphocytic lymphoma: immunophenotypic and cytogenetic findings.
Blood.
1987; 69: 1617–21.
[PubMed]
74.
Hashimoto Y, Nakamura N, Kuze T.
et al. Multiple lymphomatous polyposis of the gastrointestinal tract is a heterogeneous group that includes mantle cell lymphoma and follicular lymphoma: analysis of somatic mutation of the immunoglobulin heavy chain gene variable region.
Hum Pathol.
1999; 30: 581–7.
[PubMed]
75.
Isaacson PG, MacLennan KA, Subbuswamy SG.
Multiple lymphomatous polyposis of the gastrointestinal tract.
Histopathology.
1984; 8: 641–56.
[PubMed]
76.
McBride JA, Rodriguez J, Luthra R.
et al. T-cell-rich B large-cell lymphoma simulating lymphocyte-rich Hodgkin's disease.
Am J Surg Pathol.
1996; 20: 193–201.
[PubMed]
77.
Alizadeh A, Eisen M, Davis R.
et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
Nature.
2000; 403: 503–11.
[PubMed]
78.
Medeiros LJ, Weiss LM, Picker LJ.
et al. Expression of LFA-1 in non-Hodgkin's lymphoma.
Cancer.
1989; 63: 255–9.
[PubMed]
79.
Stauder R, Eisterer W, Thaler J, Gunthert U.
CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor.
Blood.
1995; 85: 2885–999.
[PubMed]
80.
Gascoyne RD, Adomat SA, Krajewski S.
et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma.
Blood.
1997; 90: 244–51.
[PubMed]
81.
Kramer M, Hermans J, Parker J, Krol A.
Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study.
J Clin Oncol.
1996; 14: 2131–8.
[PubMed]
82.
Sanchez E, Chacon I, Plaza M, Munoz E.
Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins.
J Clin Oncol.
1998; 16: 1931–9.
[PubMed]
83.
Skinnider BF, Horsman DE, Dupuis B, Gascoyne RD.
Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities.
Hum Pathol.
1999; 30: 803–8.
[PubMed]
84.
Bunn P Jr, Schein P, Banks P, DeVita V Jr.
Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited.
Blood.
1976; 47: 3.
[PubMed]
85.
van Besien K, Ha C, Murphy S, McLaughlin P.
Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma.
Blood.
1998; 91: 1178–84.
[PubMed]
86.
Moeller P, Matthaei-Maurer U, Hofmann WJ.
et al. Immunophenotypic similarities of mediastinal clear-cell lymphoma and sinusoidal (monocytoid) B cells.
Int J Cancer.
1989; 43: 10–6.
[PubMed]
87.
Yumura-Yagi K, Ishihara S, Hara J.
et al. Poor prognosis of mediastinal non-Hodgkin's lymphona with an immature phenotype of CD2+, Cd7 (orCD5)+, CD3-, CD4-, and CD8-
Cancer.
1989; 63: 671–4.
[PubMed]
88.
van Besien K, Kelta M, Bahaguna P.
Primary mediastinal B-cell lymphoma: a review of pathology and management.
J Clin Oncol.
2001; 19: 1855–64.
[PubMed]
89.
Jacobson J, Aisenberg A, Lamarre L.
et al. Mediastinal large cell lymphoma: an uncommon subset of adult lymphoma curable with combined modality therapy.
Cancer.
1988; 62: 1893–8.
[PubMed]
90.
Ferry JA, Harris NL, Picker LJ.
et al. Intravascular lymphomatosis (malignant angioendotheliomatosis). A B-cell neoplasm expressing surface homing receptors.
Mod Pathol.
1988; 1: 444–52.
[PubMed]
91.
DiGiuseppe JA, Nelson WG, Seifter EJ.
et al. Intravascular lymphomatosis: a clinicopathologic study of 10 cases and assessment of response to chemotherapy.
J Clin Oncol.
1994; 12: 2573–9.
[PubMed]
92.
Jaffe E.
Classification of natural killer (NK)-cell and NK-like T-cell malignancies.
Blood.
1996; 87: 1207–10.
[PubMed]
93.
Kanavaros P, Lescs M, Briere J.
et al. Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus.
Blood.
1993; 81: 2688–95.
[PubMed]
94.
Gonzalez C, Medeiros L, Braziel R, Jaffe E.
T-cell lymphoma involving subcutaneous tissue: a clinicopathologic entity commonly associated with hemophagocytic syndrome.
Am J Surg Pathol.
1991; 15: 17–27.
[PubMed]
95.
Murray A, Cuevas E, Jones D, Wright D.
Study of the immunohistochemistry and T-cell clonality of enteropathy-associated T-cell lymphoma.
Am J Pathol.
1995; 146: 509–19.
[PubMed]
96.
Farcet J, Gaulard P, Marolleau J.
et al. Hepatosplenic T-cell lymphoma: sinusoidal localization of malignant cells expressing the T-cell receptor g/d.
Blood.
1990; 75: 2213–9.
[PubMed]
97.
Cooke C, Krenacs L, Stetler-Stevenson M.
et al. Hepatosplenic T-cell lymphoma. a distinct clinicopathologic entity of cytotoxic gd T-cell origin.
Blood.
1996; 88: 4265–74.
[PubMed]
98.
Fizzera G, Moran E, Rappaport H.
Angio-immunoblastic lymphadenopathy. Diagnosis and clinical course.
Am J Med.
1975; 59: 803.
[PubMed]
99.
Lukes R, Tindle B. Immunoblastic lymphadenopathy. A hyperimmune entity resembling Hodgkin's disease. N Engl J Med 1975;292:1-8.
[PubMed].
100.
Watanabe S, Sato Y, Shimoyama M.
et al. Immunoblastic lymphadenopathy, angioimmunoblastic lymphadenopathy, and IBL-like T-cell lymphoma. A spectrum of T-cell neoplasia.
Cancer.
1986; 58: 2224–32.
[PubMed]
101.
Kadin M, Morris S.
The t(2;5) in human lymphomas.
Leuk Lymphoma.
1998; 29: 249–56.
[PubMed]
102.
Schwarting R, Gerdes J, Durkop H.
et al. BER-H2. a new anti-Ki-1 (CD30) monoclonal antibody directed at a formal-resistant epitope.
Blood.
1989; 74: 1678–89.
[PubMed]
103.
Pulford K, Lamant L, Morris SW.
et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1.
Blood.
1997; 89: 1394–404.
[PubMed]
104.
Gascoyne RD, Aoun P, Wu D.
et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma.
Blood.
1999; 93: 3913–21.
[PubMed]
105.
Shiota M, Nakamura S, Ichinohasama R.
et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity.
Blood.
1995; 86: 1954–60.
[PubMed]
106.
Shulman L, Frisard B, Antin J.
et al. Primary Ki-1 anaplastic large-cell lymphoma in adults: clinical characteristics and therapeutic outcome.
J Clin Oncol.
1993; 11: 937–42.
[PubMed]
107.
Tilly H, Gaulard P, Lepage E.
et al. Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome.
Blood.
1997; 90: 3727–34.
[PubMed]
108.
Zinzani P, Bendandi M, Martelli M.
et al. Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients.
J Clin Oncol.
1996; 14: 955–62.
[PubMed]
109.
Brouet JC, Rabian C, Gisselbrecht C, Flandrin G.
Clinical and immunological study of non-Hodgkin's T cell lymphomas (cutaneous and lymphoblastic lymphomas excluded).
Br J Haematol.
1984; 57: 315–27.
[PubMed]
110.
Link MP, Stewart SJ, Wrnke RA, Levy R.
Discordance between surface and cytoplasmic expression of the leu-4 (T3) antigen in thymocytes and in blast cells from childhood T lymphoblastic malignancies.
J Clin Invest.
1985; 76: 248–53.
[PubMed]
111.
Nadler LM, Reinherz EL, Weinstein HJ.
et al. Heterogeneity of T cell lymphoblastic malignancies.
Blood.
1980; 55: 806–10.
[PubMed]
112.
Hollema H, Poppema S.
T-lymphoblastic and peripheral T-cell lymphomas in the northern part of The Netherlands. An immunologic study of 29 cases.
Cancer.
1989; 64: 1620–8.
[PubMed]
113.
Crist WM, Shuster JJ, Falletta J.
et al. Clinical features and outcome in childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation. A pediatric oncology group study.
Blood.
1988; 72: 1891–7.
[PubMed]
114.
Streuli R, Kaneko Y, Variakojis D.
et al. Lymphoblastic lymphoma in adults.
Cancer.
1981; 47: 2510.
[PubMed]
115.
Copelan E, McGuire E.
The biology and treatment of acute lymphoblastic leukemia in adults.
Blood.
1995; 85: 1151–68.
[PubMed]
116.
Soslow R, Baergen R, Warnke R.
B-lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically similar aggressive lymphomas with blastic morphology.
Cancer.
1999; 85: 2648–54.
[PubMed]
117.
Yano T, van Krieken J, Magrath I.
et al. Histogenetic correlations between subcategories of small non-cleaved cell lymphomas.
Blood.
1992; 79: 1282–90.
[PubMed]
118.
Gregory CD, Murray RJ, Edwards CF, Rickinson AB.
Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance.
J Exp Med.
1988; 167: 1811–24.
[PubMed]
119.
Mann RB, Jaffe ES, Braylen RC.
et al. Non-endemic Burkitts lymphoma. A B cell tumor related to germinal centers.
N Engl J Med.
1976; 295: 685–91.
[PubMed]
120.
Bernstein R, Pinto MR, Behr A, Mendelow B.
Chromosome 3 abnormalities in acute nonlymphocytic leukemia (ANLL) with abnormal thrombopoiesis report of three patients with a “new” inversion anomaly and a further case of homologous translocation.
Blood.
1982; 60: 613–6.
[PubMed]
121.
Kaneko Y, Abe R, Sampi K, Sakurai M.
Analysis of chromosome findings in non-Hodgkin's lymphomas.
Cancer Genet Cytogenet.
1982; 5: 107.
[PubMed]
122.
Kaneko Y, Maseki N, Homma C.
et al. Chromosome translocation involving band 7q35 or 7p15 in childhood T-cell leukemia/lymphoma.
Blood.
1988; 72: 534.
[PubMed]
123.
Le Beau M.
Chromosomal abnormalities in non-Hodgkin's lymphoma.
Semin Oncol.
1990; 17: 20.
[PubMed]
124.
Levine E, Arthur D, Frizzera G.
et al. There are differences in cytogenic abnormalities among histologic subtypes of the non-Hodgkin's lymphomas.
Blood.
1985; 66: 1414.
[PubMed]
125.
ISCN. An international system for human cytogenetic nomenclature. Basel, Switzerland. Cytogenet Cell Genet 1985.
126.
Bloomfield C, Arthur D, Frizzrera G.
et al. Non-random chromosome abnormalities in lymphoma.
Cancer Res.
1983; 43: 2975.
[PubMed]
127.
McKeithan T, Takimoto G, Ohno H, Bjorling V.
BCL3 rearrangements and t(14;19) in chronic lymphocytic leukemia and other B-cell malignancies: a molecular and cytogenetic study.
Genes Chromosomes Cancer.
1997; 20: 64–72.
[PubMed]
128.
Panayiotidis P, Kotsi P.
Genetics of small lymphocyte disorders.
Semin Hematol.
1999; 36: 171–7.
[PubMed]
129.
Offit K, Parsa N, Jhanwar S.
et al. Clusters of chromosome 9 aberrations are associated with clinico-pathologic subsets of non-Hodgkin's lymphoma.
Genes Chromosom Cancer.
1993; 7: 1–7.
[PubMed]
130.
Ott G, Katzenberger T, Greiner A, Kalla J.
The t(11;18)(q21;q21) chromosome translocation is a frequent and specific aberration in low-grade but not high-grade malignant non-Hodgkin's lymphomas of the mucosa-associated lymphoid tissue (MALT-) type.
Cancer Res.
1997; 57: 3944–8.
[PubMed]
131.
Mateo M, Mollejo M, Villuendas R, Algara P.
7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma.
Am J Pathol.
1999; 154: 1583–9.
[PubMed]
132.
Troussard X, Mauvieux L, Radford-Weiss I, Rack K.
Genetic analysis of splenic lymphoma with villous lymphocytes. a Group Francais d'Hematologie Cellulaire (GFHC) study.
Br J Haematol.
1998; 101: 712–21.
[PubMed]
133.
Rowley J.
Chromosome studies in non-Hodgkin's lymphomas. The role of the 14;=+18 translocation.
J Clin Oncol.
1988; 6: 919.
[PubMed]
134.
Tsujimoto Y, Yunis J, Onorato-Showe L.
et al. Molecular cloning of the chromsomal breakpoint of B cell lymphomas and leukemias with the t(11;14) chromosome translocation.
Science.
1984; 224: 1403.
[PubMed]
135.
De Wolf-Peeters C, Pittaluga S.
Mantle-cell lymphoma.
Ann Oncol.
1994; 5(Suppl 1): 35–37.
[PubMed]
136.
Cuneo A, Bigoni R, Rigolin G, Roberti M.
Cytogenetic profile of lymphoma of follicle mantle lineage: correlation with clinicobiologic features.
Blood.
1999; 93: 1372–80.
[PubMed]
137.
Miki T, Kawamata N, Arai A.
et al. Molecular cloning of the breakpoint for 3q27 translocation in B-cell lymphomas and leukemias.
Blood.
1994; 83: 217–22.
[PubMed]
138.
Kerchaert J, Deweindt C, Tilly H.
et al. LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas.
Nat Genet.
1993; 5: 66–70.
[PubMed]
139.
Lo Coco F, Ye B, Lista F.
et al. Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma.
Blood.
1994; 83: 1757–9.
[PubMed]
140.
Baron B, Nucifora G, McCabe N.
et al. Identification of the gene associated with the recurring chromosomal translocations t(3;14) (q27; q32) and t(3.22)(q27;q11) in B-cell lymphomas.
Proc Natl Acad Sci USA.
1993; 90: 5262.
[Free Full text in PMC]
[PubMed]
141.
Bastard C, Deweindt C, Kerckaert J.
et al. LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients.
Blood.
1994; 83: 2423–7.
[PubMed]
142.
Elenitoba-Johnson K, Gascoyne R, Lim M.
et al. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma.
Blood.
1998; 91: 4677–85.
[PubMed]
143.
Lo Coco F, Gaidano G, Louie D.
et al. p53 Mutations are associated with histologic transformation of follicular lymphoma.
Blood.
1993; 82: 2289–95.
[PubMed]
144.
Tilly H, Rossi A, Stamatoullas A.
et al. Prognostic value of chromosomal abnormalities in follicular lymphoma.
Blood.
1994; 84: 1043–9.
[PubMed]
145.
Matolcsy A, Casali P, Warnke R, Knowles D.
Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated bcl-2-gene.
Blood.
1996; 88: 3937–44.
[PubMed]
146.
Lossos IS, Levy R.
Higher-grade transformation of follicle center lymphoma is associated with somatic mutation of the 5′ noncoding regulatory region of the BCL-6 gene.
Blood.
2000; 96: 635–9.
[PubMed]
147.
Rao P, Houldsworth J, Dyomina K, Parsa N.
Chromosomal and gene amplification in diffuse large B-cell lymphoma.
Blood.
1998; 92: 234–40.
[PubMed]
148.
Cigudosa J, Parsa N, Louie D, Filippa D.
Cytogenetic analysis of 363 consecutively ascertained diffuse large B-cell lymphomas.
Genes Chromosomes Cancer.
1999; 25: 123–33.
[PubMed]
149.
Boehm T, Baer R, Lavenir I.
et al. The mechanism of chromosomal translocation t(11;14) involving the T-cell receptor C-delta locus on human chromosome 14q11 and a transcribed region of chromosome 11p15.
EMBO J.
1988; 7: 385–94.
[PubMed]
[Free Full text in PMC]
150.
Caccia N, Burns G, Kirsch I.
et al. T-cell receptor alpha chain genes are located on chromosome 14q12 in humans.
J Exp Med.
1985; 151: 1125.
[PubMed]
151.
Caccia N, Kronenberg M, Saxe D.
et al. The T-cell receptor beta chain genes are located on chromosome 6 in mice and chromosome 7 in humans.
Cell.
1984; 37: 1091.
[PubMed]
152.
Hecht F, Morgan R, Hecht B, Smith S.
Common region on chromosome 14 in T-cell leukemia and lymphoma.
Science.
1984; 226: 1445.
[PubMed]
153.
Schlegelberger B, Himmler A, Godde E.
et al. Cytogenetic findings in peripheral T-cell lymphomas as a basis for distinguishing low-grade from high-grade lymphomas.
Blood.
1994; 83: 505–11.
[PubMed]
154.
Ong ST, Le Beau MM.
Chromosomal abnormalities and molecular genetics of non-Hodgkin's lymphoma.
Semin Oncol.
1998; 25: 447–60.
[PubMed]
155.
Lamant L, Dastugue N, Pulford K, Delsol G.
A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation.
Blood.
1999; 93: 3088–95.
[PubMed]
156.
Wang C, Tien H, Lin M.
et al. Consistent presence of isochromosome 7q in hepatosplenic T gamma/delta lymphoma: a new cytogenetic-clinicopathologic entity.
Genes Chromosomes Cancer.
1995; 12: 161–4.
[PubMed]
157.
Dalla-Favera R, Bregni M, Erikson J.
et al. Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells.
Proc Natl Acad Sci USA.
1982; 79: 7824.
[Free Full text in PMC]
[PubMed]
158.
Pelicci P, Knowles D, Magrath I, Dalla-Favera R.
Chromosomal breakpoint and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma.
Proc Natl Acad Sci USA.
1986; 83: 2984.
[Free Full text in PMC]
[PubMed]
159.
Croce C, Erikson J, Ar-Rushdi A.
et al. Translocated c-myc oncogene of Burkitt lymphoma is transcribed in plasma cells and repressed in lymphoblastoid cells.
Proc Natl Acad Sci USA.
1984; 81: 3170.
[Free Full text in PMC]
[PubMed]
160.
Lenoir G, Preud'homme J, Bernheim A, Berger R.
Correlations between immunoglobulin light chain expression and variant translocation in Burkitt lymphoma.
Nature.
1982; 298: 474.
[PubMed]
161.
Adams J, Harris A, Pinkert C.
et al. The c-myc oncogene driven by immunogloblin enhancers induces lymphoid malignancy in transgenic mice.
Nature.
1985; 318: 533.
[PubMed]
162.
Bakhski A, Jensen J, Goldman P.
et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas. clustering around j; zh on chromosome 14 and near a transcriptional unit on 18.
Cell.
1985; 41: 899.
[PubMed]
163.
Korsmeyer S.
Bcl-2 initiates a new category of oncogenes: regulators of cell death.
Blood.
1992; 80: 879–86.
[PubMed]
164.
Ngan B, Chen-Levy Z, Weiss L.
et al. Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation.
N Engl J Med.
1988; 318: 1638.
[PubMed]
165.
Tang S, Visser L, Hepperle B.
et al. Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma. An analysis of 83 cases.
J Clin Oncol.
1994; 12: 149–54.
[PubMed]
166.
Yunis J. Bcl-2 oncogene rearrangement in follicular and diffuse large-cell and mixed-cell lymphoma.
Cancer Cells.
1989; 7: 37–40.
167.
Hockenbery DM, Oltvai ZN, Yin XM.
et al. Bcl-2 functions in an antioxidant pathway to prevent apoptosis.
Cell.
1993; 75: 241–51.
[PubMed]
168.
McDonnell TJ, Deane N, Platt FM.
et al. Bcl-2-immunoglobulin transgenic mice demonstrated extended B cell survival and follicular lymphoproliferation.
Cell.
1989; 57: 79–88.
[PubMed]
169.
Stilgenbauer S, Schaffner C, Winkler D.
et al. The ATM gene in the pathogenesis of mantle-cell lymphoma.
Ann Oncol.
2000; 11: 127–30.
[PubMed]
170.
Shaffer AL, Yu X, He Y.
et al. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control.
Immunity.
2000; 13: 199–212.
[PubMed]
171.
Migliazza A, Martinotti S, Chen W.
et al. Frequent somatic hypermutation of the 5′ noncoding region of the BCL6 gene in B-cell lymphoma.
Proc Natl Acad Sci USA.
1995; 92: 12520–4.
[Free Full text in PMC]
[PubMed]
172.
Hernandez L, Pinyol M, Hernandez S.
et al. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations.
Blood.
1999; 94: 3265–8.
[PubMed]
173.
Morris S, Kirstein M, Valentine M.
et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkins lymphoma.
Science.
1994; 263: 1281–4.
[PubMed]
174.
Hamada T, Yonetani N, Ueda C, Maesako Y.
Expression of the PAX5/BSAP transcription factor in haematological tumour cells and further molecular characterization of the t(9;14)(p13;q32) translocation in B-cell non-Hodgkin's lymphoma.
Br J Haematol.
1998; 102: 691–700.
[PubMed]
175.
Morrison A, Jager U, Chott A, Schebesta M.
Deregulated PAX-5 transcription from a translocated IgH promoter in marginal zone lymphoma.
Blood.
1998; 92: 3865–78.
[PubMed]
176.
Iida S, Rao P, Ueda R, Chaganti R.
Chromosomal rearrangement of the PAX-5 locus in lymphoplasamacytic lymphoma with t(9;14)(p13;q32).
Leuk Lymphoma.
1999; 34: 25–33.
[PubMed]
177.
Zhang Q, Siebert R, Yan M, Hinzmann B.
Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32).
Nat Genet.
1999; 22: 63–8.
[PubMed]
178.
Dierlamm J, Baens M, Wlodarska I, Stefanova-Ouzounova M.
The apoptosis inhibitor gene AP12 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21)p6 associated with mucosa-associated lymphoid tissue lymphomas.
Blood.
1999; 93: 3601–9.
[PubMed]
179.
Moormeier J, Williams S.
The staging of non-Hodgkin's lymphomas.
Semin Oncol.
1990; 17: 43–50.
[PubMed]
180.
Anderson T, Chabner B, Young R.
et al. Malignant lymphomas: the histology and staging of 473 patients at the National Cancer Institute.
Cancer.
1982; 50: 2699.
[PubMed]
181.
Eby N, Grufferman S, Flannelly C.
et al. Increasing incidence of primary brain lymphoma in the US.
Cancer.
1988; 62: 2461.
[PubMed]
182.
L'Hoste R, Filippa D, Lieberman P, Bretsky S.
Primary pulmonary lymphomas: a clinicopathologic analysis of 36 cases.
Cancer.
1984; 54: 1397.
[PubMed]
183.
Mentzer S, Reilly J, Skarin A, Sugarbaker D.
Patterns of lung involvement by malignant lymphoma.
Surgery.
1993; 113: 507–14.
[PubMed]
184.
Haber D, Mayer R.
Primary gastrointestinal lymphoma.
Semin Oncol.
1988; 15: 154.
[PubMed]
185.
Isaacson P, Wright D.
Extranodal malignant lymphoma arising from mucosa-associated lymphoid tissue.
Cancer.
1984; 53: 2515.
[PubMed]
186.
Mynster T, Hultberg B, Bulow S.
Multiple lymphomatous polyposis of the colon and rectum. Report of a case and review of the literature.
Scand J Gastroenterol.
1994; 29: 545–9.
[PubMed]
187.
Bostwick D, Mann R.
Malignant lymphomas involving the prostate; a study of 13 cases.
Cancer.
1985; 56: 2932.
[PubMed]
188.
Paladugu B, Bearman R, Rappaport H.
Maliganant lymphoma with primary manifestation in the gonad.
Cancer.
1980; 45: 561.
[PubMed]
189.
Woolley P III, Osborne C, Levi J.
et al. Extranodal presentation of non-Hodgkin's lymphoma in the testis.
Cancer.
1976; 38: 1026.
[PubMed]
190.
Aozasa K, Inoue A, Tajima K.
et al. Malignant lymphoma of the thyroid gland. Analysis of 79 patients with emphasis on histologic prognostic factors.
Cancer.
1986; 58: 100.
[PubMed]
191.
Gill P, Chandraratna P, Meyer P, Levine A.
Cardiac involvement at initial presentation.
J Clin Oncol.
1987; 5: 216.
[PubMed]
192.
Gleeson M, Bennett M, Cawson R.
Lymphoma of the salivary gland.
Cancer.
1986; 58: 699.
[PubMed]
193.
Harris G, Tio F, Von Hodd D.
Primary adrenal lymphoma.
Cancer.
1989; 63: 799.
[PubMed]
194.
Rosenberg S.
Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas.
Cancer Treat Rep.
1977; 61: 1023.
[PubMed]
195.
Swan F Jr, Velasquez WS, Tucker S.
et al. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels.
J Clin Oncol.
1989; 7: 1518–27.
[PubMed]
196.
Velasquez WS, Jagannath S, Tucker SL.
et al. Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data.
Blood.
1989; 74: 551–7.
[PubMed]
197.
Takagi S, Tsunoda S, Tanaka O.
Bone marrow involvement in lymphoma: the importance of marrow magnetic resonance imaging.
Leuk Lymphoma.
1998; 29: 515–22.
[PubMed]
198.
Carr R, Barrington S, Madan B, O'Doherty M.
Detection of lymphoma in bone marrow by whole-body positron emission tomography.
Blood.
1998; 91: 3340–6.
[PubMed]
199.
Jerusalem G, Beguin Y, Najjar F.
et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL).
Ann Oncol.
2001; 12: 825–30.
[PubMed]
200.
Spaepen K, Stroobants S, Dupont P.
et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma. Is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
J Clin Oncol.
2001; 19: 414–9.
[PubMed]
201.
Cleary M, Chao J, Warnke R, Sklar J.
Immunoglobulin gene rearrangement as a diagnostic criterion of B-cell lymphoma.
Proc Natl Acad Sci U S A.
1984; 81: 593.
[Free Full text in PMC]
[PubMed]
202.
Stetler-Stevenson M, Raffeld M, Cohen P, Cossman J.
Detection of occult follicular lymphoma by specific DNA amplification.
Blood.
1988; 72: 1822.
[PubMed]
203.
Lee M, Chang K, Cabanillas F.
et al. Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification.
Science.
1987; 237: 175.
[PubMed]
204.
Saiki R, Gelfand D, Stoffel S.
et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.
Science.
1988; 239: 487.
[PubMed]
205.
Gribben J, Neuberg D, Freedman A.
et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma.
Blood.
1993; 81: 3449–57.
[PubMed]
206.
Gribben JG, Freedman AS, Neuberg D.
et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma.
N Engl J Med.
1991; 325: 1525–33.
[PubMed]
207.
Lopez-Guillermo A, Cabanillas F, McLaughlin P, Smith T.
The clinical significance of molecular response in indolent follicular lymphomas.
Blood.
1998; 91: 2955–60.
[PubMed]
208.
International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma.
N Engl J Med.
1993; 329: 987–94.
[PubMed]
209.
Miller T, Dahlberg S, Cassady J, Adelstein D.
Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.
N Engl J Med.
1998; 339: 21–6.
[PubMed]
210.
Shenkier TN, Voss N, Fairey R.
et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma. An 18-year experience from the British Columbia Cancer Agency.
J Clin Oncol.
2002; 20: 197–204.
[PubMed]
211.
Armitage J, Weisenburger D, Hutchins M.
et al. Chemotherapy for diffuse large-cell lymphoma. Rapidly responding patients have more durable remission.
J Clin Oncol.
1986; 4: 160.
[PubMed]
212.
Kaplan W, Southee A, Annese M. et al. Evaluating low and intermediate-grade non-Hodgkin's lymphoma (NHL) with Gallium-67 (Ga) and Thallium-201 (TI) imaging.
J Nucl Med.
1990; 31: 793.
213.
Kaplan W, Jochelson M, Herman T.
et al. Gallium-67 imaging: a predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma.
J Clin Oncol.
1990; 8: 1966.
[PubMed]
214.
Bastion Y, Coiffier B.
Is the International Prognostic Index for aggressive lymphoma patients useful for follicular lymphoma patients?
J Clin Oncol.
1994; 12: 1340–2.
[PubMed]
215.
Lopez-Guillermo A, Montserrat E, Bosch F.
et al. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphomas.
J Clin Oncol.
1994; 12: 1343–8.
[PubMed]
216.
Federico M, Vitolo U, Zinzani P.
et al. Prognosis of follicular lymphoma. a predictive model based on a retrospective analysis of 987 cases.
Blood.
2000; 95: 783–9.
[PubMed]
217.
Decaudin D, Lepage E, Brousse N.
et al. Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients-a study of the groupe d'Etude des lymphomes de l'Adulte.
J Clin Oncol.
1999; 17: 2499–505.
[PubMed]
218.
Weisdorf D, Andersen J, Glick J, Oken M.
Survival after relapse of low-grade non-Hodgkin's lymphoma. Implications for marrow transplantation.
J Clin Oncol.
1992; 10: 942–7.
[PubMed]
219.
Grogan TM, Lippman SM, Spier CM.
et al. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67.
Blood.
1988; 71: 1157–60.
[PubMed]
220.
Koduru P, Raju K, Vadmal V, Menezes G.
Correlation between mutation in p53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma.
Blood.
1997; 90: 4078–91.
[PubMed]
221.
Ichikawa A, Kinoshita T, Watanabe T, Kato H.
Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma.
N Engl J Med.
1997; 337: 529–34.
[PubMed]
222.
Hill M, MacLennan K, Cunningham D, Vaughan Hudson B.
Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma. A British National Lymphoma Investigation study.
Blood.
1996; 88: 1046–51.
[PubMed]
223.
Cheng A-L, Chen Y-C, Wang C-H.
et al. Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades-should peripheral T-cell lymphoma be considered separately.
J Clin Oncol.
1989; 7: 725–31.
[PubMed]
224.
Grogan T, Lippman S, Spier C.
et al. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by monoclonal antibody Ki-67.
Blood.
1988; 71: 1157.
[PubMed]
225.
Horning SJ, Doggert RS, Warnke RA.
et al. Clinical relevance of immunologic phenotype in diffuse large cell lymphoma.
Blood.
1984; 63: 1209–15.
[PubMed]
226.
Spier CM, Grogan TM, Lippman SM.
et al. The aberrancy of immunophenotype and immunoglobulin status as indicators of prognosis in B cell diffuse large cell lymphoma.
Am J Pathol.
1988; 133: 118–26.
[PubMed]
227.
Coiffier B, Berger F, Bryon P-A, Magaud J-P.
T-cell lymphomas. Immunologic, histologic, clinical, and therapeutic analysis of 63 cases.
J Clin Oncol.
1988; 6: 1584–9.
[PubMed]
228.
Simoyama M, Ota K, Kikuchi M.
et al. Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia.
J Clin Oncol.
1988; 6: 1088.
[PubMed]
229.
Melnyk A, Rodriguez A, Pugh W, Cabannillas F.
Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma.
Blood.
1997; 89: 4514–20.
[PubMed]
230.
Ansell S, Habermann T, Kurtin P, Witzig T.
Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma.
J Clin Oncol.
1997; 15: 2296–301.
[PubMed]
231.
Miller TP, Lippman SM, Spier CM.
et al. HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma.
J Clin Invest.
1988; 82: 370–2.
[PubMed]
[Free Full text in PMC]
232.
Horst E, Meijer CJLM, Radaszkiewicz T.
et al. Adhesion molecules in the prognosis of diffuse large cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54).
Leukemia.
1990; 4: 595–9.
[PubMed]
233.
Joensuu H, Ristamaki R, Klemi P, Jalkanen S.
Lymphocyte homing receptor (CD44) expression is associated with poor prognosis in gastrointestinal lymphoma.
Br J Cancer.
1993; 68: 428–32.
[PubMed]
234.
Bauer K, Merkel D, Winter J.
et al. Prognostic implications of ploidy and proliferative activity in diffuse large cell lymphomas.
Cancer Res.
1986; 46: 3173–8.
[PubMed]
235.
Kaneko Y, Rowley J, Variakojis D.
et al. Prognostic implications of karyotype and morphology in patients with non-Hodgkin's lymphoma.
Int J Cancer.
1983; 32: 683.
[PubMed]
236.
Offit K, Wong G, Filippa D.
et al. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: clinical correlations.
Blood.
1991; 77: 1508–15.
[PubMed]
237.
Kramer M, Hermans J, Wijburg E, Philippo K.
Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma.
Blood.
1998; 92: 3152–62.
[PubMed]
238.
Macpherson N, Lesack D, Klasa R, Horsman D.
Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation.
J Clin Oncol.
1999; 17: 1558–67.
[PubMed]
239.
Preti H, Cabanillas F, Talpaz M, Tucker S.
Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma.
Ann Intern Med.
1997; 127: 186–94.
[PubMed]
240.
Legouffe E, Rodriguez C, Picot M, Richard B.
C-reactive protein serum level is a valuable and simple prognostic marker in non-Hodgkin's lymphoma.
Leuk Lymphoma.
1998; 31: 351–7.
[PubMed]
241.
Salles G, Bienvenu J, Bastion Y, Barbier Y.
Elevated circulating levels of TNF-alpha and its p55 soluble receptor are associated with an adverse prognosis in lymphoma patients.
Br J Haematol.
1996; 93: 352–9.
[PubMed]
242.
Niitsu N, Okamoto M, Okabe-Kado J.
et al. Serum nm23-H1 protein as a prognostic factor for indolent non-Hodgkin's lymphoma.
Leukemia.
2001; 15: 832–9.
[PubMed]
243.
Salven P, Teerenhovi L, Joensuu H.
A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma.
Blood.
1999; 94: 3334–9.
[PubMed]
244.
Gribben J, Freedman A, Woo S.
et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment.
Blood.
1991; 78: 3275–80.
[PubMed]
245.
Lambrechts A, Hupkes P, Dorssers L, Van't Veer M.
Clinical significance of t(14;18)-positive cells in the circulation of patients with stage III or IV follicualr non-Hodgkin's lymphoma during the first remission.
J Clin Oncol.
1994; 12: 1541–6.
[PubMed]
246.
Shipp MA, Ross KN, Tamayo P.
et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.
Nat Med.
2002; 8: 68–74.
[PubMed]
247.
MacManus M, Hoppe R.
Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University.
J Clin Oncol.
1996; 14: 1282–90.
[PubMed]
248.
MacManus MP, Rainer Bowie CA, Hoppe RT.
What is the prognosis for patients who relapse after primary radiation therapy for early-stage low-grade follicular lymphoma?
Int J Radiat Oncol Biol Phys.
1998; 42: 365–71.
[PubMed]
249.
Chen MG, Prosnitz LR, Gonzalez-Serva A, Fischer DB.
Results of radiotherapy in control of stage I and II non-Hodgkin's lymphoma.
Cancer.
1979; 43: 1245–54.
[PubMed]
250.
McLaughlin P, Fuller LM, Velasquez WS.
et al. Stage I-II follicular lymphoma. Treatment results for 76 patients.
Cancer.
1986; 58: 1596–602.
[PubMed]
251.
Monfardini S, Banfi A, Bonadonna G.
et al. Improved five year survival after combined radiotherapy-chemotherapy for stage I-II non-Hodgkin's lymphoma.
Int J Radiat Oncol Biol Phys.
1980; 6: 125–34.
[PubMed]
252.
Toonkel LM, Fuller LM, Gamble JF.
et al. Laparotomy staged I an II non-Hodgkin's lymphomas: preliminary results of radiotherapy an adjunctive chemotherapy.
Cancer.
1980; 45: 249–60.
[PubMed]
253.
Kelsey S, Newland A, Hudson G, Jelliffe Q.
A British National Lymphoma Investigation ramdomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkin's lymphoma.
Med Oncol.
1994; 11: 19–25.
[PubMed]
254.
Tsang RW, Gospodarowicz MK, Pintilie M.
et al. Stage I and II MALT lymphoma. results of treatment with radiotherapy.
Int J Radiat Oncol Biol Phys.
2001; 50: 1258–64.
[PubMed]
255.
Gattiker HH, Wiltshaw E, Galton DA.
Spontaneous regression in non-Hodgkin's lymphoma.
Cancer.
1980; 45: 2627–32.
[PubMed]
256.
Krikorian JG, Portlock CS, Cooney P, Rosenberg SA.
Spontaneous regression of non-Hodgkin's lymphoma: a report of nine cases.
Cancer.
1980; 46: 2093–9.
[PubMed]
257.
Hoppe RT, Kushlan P, Rosenberg SA, Brown BW.
The treatment of advanced stage favorable histology non-Hodgkin's lymphoma. A preliminary report of a randomized trial comparing single agent chemotherapy, and whole body irradiation.
Blood.
1981; 58: 592–8.
[PubMed]
258.
Johnson RE, Canellos GP, Young RC.
et al. Chemotherapy (cyclophosphamide, vincristine, and prednisone) versus radiotherapy (total body irradiation) for stage III-IV poorly differentiated lymphocytic lymphoma.
Cancer Treat Rep.
1977; 62: 321–5.
[PubMed]
259.
Gallagher CJ, Gregory WM, Jones AE.
et al. Follicular lymphoma. Prognostic factors for response and survival.
J Clin Oncol.
1986; 4: 1470–80.
[PubMed]
260.
Ezdinli EZ, Harrington DP, Kucuk O.
et al. The effect of intensive intermittent maintenance therapy in advanced low-grade non-Hodgkin's lymphoma.
Cancer.
1987; 60: 156–60.
[PubMed]
261.
Glick JH, Barnes JM, Ezdinli EZ.
et al. Nodular mixed lymphoma. Results of a randomized trial failing to confirm prolonged disease-free suvival with COPP chemotherapy.
Blood.
1981; 58: 920–5.
[PubMed]
262.
Jones SE, Grozea PN, Miller TP.
et al. Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone of with levamisole or with levamisole plus BCG for malignant lymphoma: a Southwest Oncology Group Study.
J Clin Oncol.
1985; 3: 1318–24.
[PubMed]
263.
Young RC, Johnson RE, Canellos GP.
et al. Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination.
Cancer Treat Rep.
1977; 61: 1153–9.
[PubMed]
264.
Anderson T, Fisher RI, De Vita VT.
et al. Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term follow-up.
Cancer Treat Rep.
1977; 61: 1057–66.
[PubMed]
265.
Longo DL, Young RC, Hubard SM.
et al. Prolonged initial remission in patients with nodular mixed lymphoma.
Ann Intern Med.
1984; 100: 651–6.
[PubMed]
266.
Cabanillas F, Smith T, Bodey GP.
et al. Nodular malignant lymphomas: factors affecting complete response rate and survival.
Cancer.
1979; 44: 1983–9.
[PubMed]
267.
Ezdinli EZ, Costello WG, Icli F.
et al. Nodular mixed lymphocytic-histiocytic lymphoma (NM): response and survival. Eastern Cooperative Oncology Group.
Cancer.
1980; 45: 261–7.
[PubMed]
268.
Morrison V, Peterson B.
Combination chemotherapy in the treatment of follicualr low-grade lymphoma.
Leuk Lymphoma.
1993; 10: 29–33.
[PubMed]
269.
McLaughlin P, Fuller LM, Velasquez WS.
et al. Stage III follicular lymphoma: durable remissions with a combined chemotherapy-radiotherapy regimen.
J Clin Oncol.
1987; 5: 867–74.
[PubMed]
270.
Young RC, Longo DL, Glatstein E.
et al. The treatment of indolent lymphomas: watchful waiting V aggressive combined modality treament.
Semin Hematol.
1988; 25: 11–6.
[PubMed]
271.
Smalley R, Andersen J, Hawkins M.
et al. Interferon alfa combined with cytotoxic chemotherapy for patients with non-hodgkin's lymphoma.
N Engl J Med.
1992; 327: 1336–41.
[PubMed]
272.
Solal-Celigny P, Lepage E, Brousse N.
et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.
N Engl J Med.
1993; 329: 1608–14.
[PubMed]
273.
Arranz R, Garcia-Alfonso P, Sobrino P.
et al. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization.
J Clin Oncol.
1998; 16: 1538–46.
[PubMed]
274.
Hagenbeek A, Carde P, Meerwaldt J.
et al. Maintenance of remission with human recombinant interferon alfa-2a in patients withstages III and IV low-grade malignant non-Hodgkin's lymphoma.
J Clin Oncol.
1998; 16: 41–7.
[PubMed]
275.
Solal-Celigny P, Lepage E, Brousse N.
et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 trial.
J Clin Oncol.
1998; 16: 2332–8.
[PubMed]
276.
Chun H, Leyland-Jones B, Cheson D.
Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.
J Clin Oncol.
1991; 9: 175–88.
[PubMed]
277.
Hochster H, Kim K, Green M.
et al. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study.
J Clin Oncol.
1992; 10: 28–32.
[PubMed]
278.
Kay A, Saven A, Carrera C.
et al. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas.
J Clin Oncol.
1992; 10: 371–7.
[PubMed]
279.
Redman J, Cabanillas F, Velasquez W.
et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma.
J Clin Oncol.
1992; 10: 790–4.
[PubMed]
280.
Tefferi A, Witzig T, Reid J.
et al. Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma.
J Clin Oncol.
1994; 12: 569–74.
[PubMed]
281.
Whelan J, Davis C, Rule S.
et al. Fludarabine phosphate for the treatment of low grade lymphoid malignancy.
Br J Cancer.
1991; 64: 120–3.
[PubMed]
282.
Solal-Celigny P, Brice P, Brousse N.
et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte.
J Clin Oncol.
1996; 14: 514–9.
[PubMed]
283.
Hochster HS, Oken MM, Winter JN.
et al. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and long-term follow-up-a report from the Eastern Cooperative Oncology Group.
J Clin Oncol.
2000; 18: 987–94.
[PubMed]
284.
Velasquez W, Lew D, Miller T, Fisher R. SWOG 95-01: a phase II trial of a combination of fludarabine and mitoxantrone (FN) in untreated advanced low grade lymphoma. An effective, well tolerated therapy [abstract].
Proc ASCO.
1999; 18: 9a.
285.
Hagenbeek A, Eghbali H, Monfardini S. Fludarabine compared with CVP chemotherapy in newly diagnosed patients with stages III and IV low grade malignant non-Hodgkin's lymphoma. Final analysis of a prospective randomized phase III Intergroup study of 381 patients [abstract].
Blood.
2001; 98: 843a.
286.
Klasa R, Meyer R, Shustik C. et al. Fludarabine versus CVP in previously treated patients with progressive low grade non-Hodgkin's lymphomas.
Proc ASCO.
1999; 18: 9a.
287.
Multani P, Grossbard M.
Monoclonal antibody-based therapies for hematologic malignancies.
J Clin Oncol.
1998; 16: 3691–710.
[PubMed]
288.
McLaughlin P, Grillo-Lopez A, Link B.
et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
J Clin Oncol.
1998; 16: 2825–33.
[PubMed]
289.
Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18:3135–43.
[PubMed].
290.
Hainsworth JD, Burris HA III, Morrissey LH.
et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin's lymphoma.
Blood.
2000; 95: 3052–6.
[PubMed]
291.
Colombat P, Salles G, Brousse N.
et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.
Blood.
2001; 97: 101–6.
[PubMed]
292.
Kaminski MS, Zelenetz AD, Press OW.
et al. Pivotal study of iodine I-131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.
J Clin Oncol.
2001; 19: 3918–28.
[PubMed]
293.
Kaminski MS, Estes J, Zasadny KR.
et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin's lymphoma: updated results and long-term follow-up of the University of Michigan experience.
Blood.
2000; 96: 1259–66.
[PubMed]
294.
Witzig TE, White CA, Wiseman GA.
et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.
J Clin Oncol.
1999; 17: 3793–803.
[PubMed]
295.
Witzig T, Leigh B, Gordon L, Smith M. Interim results from a prospective randomized controlled trial comparing Zevalin radioimmunotherapy to rituximab immunotherapy for B-cell non-Hodgkin's lymphoma: resistance to prior chemotherapy versus response rate [abstract].
Proc Am Soc Clin Oncol.
2000; 19: 29a.
296.
Acker B, Hoppe RT, Colby TV.
et al. Histologic conversion in the non-Hodgkin's lymphomas.
J Clin Oncol.
1983; 1: 11–6.
[PubMed]
297.
Friedberg J, Neuberg D, Gribben J.
et al. Autologous bone marrow transplantation following histologic transformation of indolent B cell malignancies.
Biol Blood Marrow Transplant.
1999; 5: 262–8.
[PubMed]
298.
Williams CD, Harrison CN, Lister TA.
et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry.
J Clin Oncol.
2001; 19: 727–35.
[PubMed]
299.
Sweet D, Kinzie J, Gaeke M.
et al. Survival of patients with localized diffuse histiocytic lymphoma.
Blood.
1981; 58: 1218.
[PubMed]
300.
Longo D, Glatstein E, Duffey P.
et al. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy.
J Clin Oncol.
1989; 7: 1295–302.
[PubMed]
301.
Tondini C, Zanini M, Lombardi F.
et al. Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage i or ii histologically aggressive non-Hodgkin's lymphomas.
J Clin Oncol.
1993; 11: 720–5.
[PubMed]
302.
Jones S, Miller T, Connors J.
Long-term follow up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy.
J Clin Oncol.
1989; 7: 1186–91.
[PubMed]
303.
Horning S, Glick J, Kim K, Smith S. Final report of E1484: CHOP versus CHOP+radiotherapy for limited stage diffuse aggressive lymphoma [abstract].
Blood.
2001; 98: 724a.
304.
DeVita V Jr, Canellos G, Chabner B.
et al. Advanced diffuse histiocytic lymphoma, a potentially curable disease.
Lancet.
1975; 1: 248.
[PubMed]
305.
Coltman C, Dahlberg S, Jones S, et al. CHOP is curative in thirty percent of patients with large cell lymphoma: a twelve year Southwest Oncology Group follow-up. In:Skarin AT, editor. Advances in cancer chemotherapy. New York: Park Row; 1986. p. 71.
306.
Gaynor E, Ultman J, Colomb H, Sweet D.
Treatment of diffuse histiocytic lymphoma (DHL) with COMLA (cyclophosphamide, oncovin, methotrexate, leucovorin, cytosine, arabinoside): a 10-year experience in a single institution.
J Clin Oncol.
1985; 3: 1596–604.
[PubMed]
307.
Schein P, DeVita V, Hubbard S.
Bleomycin, Adriamycin, cyclophosphamide [pn2067mmmrm i0], vincristine and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.
Ann Intern Med.
1976; 85: 417.
[PubMed]
308.
Skarin A, Rosenthal D, Maloney W, Frei E.
Combination chemotherapy of advanced non-Hodgkin's lymphoma with bleomycin, Adriamycin, cyclophosphamide, vincristine and prednisone (BACOP).
Blood.
1977; 49: 759.
[PubMed]
309.
Skarin A, Canellos G, Rosenthal D.
et al. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high-dose methotrexate alternating with standard agent (MBACOD).
J Clin Oncol.
1983; 1: 91.
[PubMed]
310.
Fisher R, DeVita V, Hubbard S.
et al. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy.
Ann Intern Med.
1983; 98: 304.
[PubMed]
311.
Longo D, DeVita V, Duffey P.
et al. Superiority of ProMACE-CytaBOM Over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
J Clin Oncol.
1991; 9: 25–38.
[PubMed]
312.
Klimo P, Connors J.
MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma.
Ann Intern Med.
1985; 102: 596–602.
[PubMed]
313.
Coleman M, Boyd D, Beshevkin MEA. COP-BLAM treatment of large cell lymphoma: a status report. In: Skarin AT, editor. Update on treatment for diffuse large cell lymphoma. New York: Park Row; 1986. p. 63.
314.
Fisher R, Gaynor E, Dahlberg S.
et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
N Engl J Med.
1993; 328: 1002.
[PubMed]
315.
Sertoli M, Santini G, Chisesi T.
et al. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodkin's lymphoma. Cooperative Study Group.
J Clin Oncol.
1994; 12: 1366–74.
[PubMed]
316.
Meyer R, Quirt I, Skillings J.
et al. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma.
N Engl J Med.
1993; 329: 1770–6.
[PubMed]
317.
Gordon L, Harrington D, Andersen J.
et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.
New Engl J Med.
1992; 327: 1342–9.
[PubMed]
318.
Goss P.
Non-Hodgkin's lymphomas in elderly patients.
Leuk Lymphoma.
1993; 10: 147–56.
[PubMed]
319.
Gomez H, Hidalgo M, Casanova L, Colomer R.
Risk factors for treatment-related in elderly patients with aggressive non-Hodgkin's lymphoma: results in of a multivariate analysis.
J Clin Oncol.
1998; 16: 2065–9.
[PubMed]
320.
Bastion Y, Blay J, Divine M, Brice P.
Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival—a Groupe d-Etude des Lmphomas de l'Adulte study on 453 patients older than 69 years.
J Clin Oncol.
1997; 15: 2945–53.
[PubMed]
321.
Zinzani P, Storti S, Zaccaria A, Moretti L.
Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients.
Blood.
1999; 94: 33–8.
[PubMed]
322.
Meyer R, Browman G, Samosh M, Benger A.
Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma.
J Clin Oncol.
1995; 13: 2386–93.
[PubMed]
323.
Sonneveld P, de Ridder M, van der Lelie H, Neiuwenhuis K.
Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CHOP chemotherapy.
J Clin Oncol.
1995; 13: 2530–9.
[PubMed]
324.
Tirelli U, Errante D, Van Glabbeke M, Teodorovic I.
CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group.
J Clin Oncol.
1998; 16: 27–34.
[PubMed]
325.
Coiffier B, Lepage E, Briere J.
et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
N Engl J Med.
2002; 346: 235–42.
[PubMed]
326.
Glick J, McFadden E, Costello W.
et al. Nodular histiocytic lymphoma: factors influencing prognosis and implications for aggressive chemotherapy.
Cancer.
1982; 49: 840.
[PubMed]
327.
Velders G, Kluin-Nelemans J, De Boer C.
et al. Mantle-cell lymphoma: a population-based clinical study.
J Clin Oncol.
1996; 14: 1269–74.
[PubMed]
328.
Decaudin D, Bosq J, Tertian G, Nedellec G.
Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas.
J Clin Oncol.
1998; 16: 579–83.
[PubMed]
329.
Foran J, Rohatiner A, Coiffier B, Barbui T.
Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma.
J Clin Oncol.
1999; 17: 546–53.
[PubMed]
330.
Coiffier B, Haioun C, Ketterer N, Engert A.
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
Blood.
1998; 92: 1927–32.
[PubMed]
331.
Khouri I, Romaguera J, Kantarjian H, Palmer J.
Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.
J Clin Oncol.
1998; 16: 3803–9.
[PubMed]
332.
Howard OM, Gribben JG, Neuberg DS.
et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.
J Clin Oncol.
2002; 20: 1288–94.
[PubMed]
333.
Coleman C, Picozzi V Jr, Cox R.
et al. Treatment of lymphoblastic lymphoma in Adults.
J Clin Oncol.
1986; 4: 1628.
[PubMed]
334.
Sweetenham JW, Santini G, Qian W.
et al. High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group.
J Clin Oncol.
2001; 19: 2927–36.
[PubMed]
335.
Kantarjian HM, O'Brien S, Smith TL.
et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
J Clin Oncol.
2000; 18: 547–61.
[PubMed]
336.
Lopez, Tea.Small noncleaved cell lymphoma in adults: superior results for stages I-III disease.
J Clin Oncol.
1990; 8: 615–22.
[PubMed]
337.
Mashal R, Canellos G.
Small non-cleaved cell lymphoma in adults.
Am J Hemat.
1991; 38: 40.
[PubMed]
338.
Schwenn M, Blattner S, Lynch E, Weinstein H.
HiC-COM: a 2-month intensive chemotherapy regimen for children with stage III and IV Burkitt's lymphoma and B cell acute lymphoblastic leukemia.
J Clin Oncol.
1991; 9: 133–8.
[PubMed]
339.
Soussain C, Patte C, Ostronoff M.
et al. Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols.
Blood.
1995; 85: 664–74.
[PubMed]
340.
Lee EJ, Petroni GR, Schiffer CA.
et al. Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of Cancer and Leukemia Group B study 9251.
J Clin Oncol.
2001; 19: 4014–22.
[PubMed]
341.
Singer CRJ, Goldstone AH.
Clinical studies of ABMT in non-Hodgkin;s lymphoma.
Clin Haematol.
1986; 15: 105–49.
[PubMed]
342.
Armitage JO.
Bone marrow transplantation in the treatment of patients with lymphoma.
Blood.
1989; 73: 1749–58.
[PubMed]
343.
Velasquez WS, Cabanillas F, Salvador P.
et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ara-c and dexamethasone (DHAP).
Blood.
1988; 71: 117–22.
[PubMed]
344.
Goss P, Shepherd F, Scott J.
et al. Dexamethasone/ifosfamide/cisplatin/etoposide (DICE) as therapy for patients with advanced refractory non-Hodgkin's lymphoma: preliminary report of a phase II study.
Ann Oncol.
1991; 2 Suppl 1: 43–6.
[PubMed]
345.
Velasquez W, McLaughlin P, Tucker S.
et al. ESHAP—an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.
J Clin Oncol.
1994; 12: 1169–76.
[PubMed]
346.
Sparano J, Wiernik P, Leaf A, Dutcher J.
Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule-dependent effect favoring infusional administration of chemotherapy.
J Clin Oncol.
1993; 11: 1071–9.
[PubMed]
347.
Wilson W, Bryant G, Bates S.
et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.
J Clin Oncol.
1993; 11: 1573–82.
[PubMed]
348.
Guglielmi C, Gomez F, Philip T, Hagenbeek A.
Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial.
J Clin Oncol.
1998; 16: 3264–9.
[PubMed]
349.
Applebaum FR, Fefer A, Cheever MA.
et al. Treatment of non-Hodgkin's lymphoma with marrow transplantation in identical twins.
Blood.
1981; 58: 509–13.
[PubMed]
350.
van Besien K, Thall P, Korbling M, Pugh W.
Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients.
Biol Blood Marrow Transplant.
1997; 3: 150–6.
[PubMed]
351.
Chopra R, Goldstone A, Pearce R.
et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Tansplant Group Registry data.
J Clin Oncol.
1992; 10: 1690–5.
[PubMed]
352.
Ratanatharathorn V, Uberti J, Karanes C.
et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma.
Blood.
1994; 84: 1050–5.
[PubMed]
353.
Juckett M, Rowlings P, Hessner M.
et al. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up.
Bone Marrow Transplant.
1998; 21: 893–9.
[PubMed]
354.
Soiffer R, Freedman A, Neuberg D.
et al. CD6+ T-cell depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma.
Bone Marrow Transplant.
1998; 21: 1177–81.
[PubMed]
355.
Khouri IF, Saliba RM, Giralt SA.
et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.
Blood.
2001; 98: 3595–9.
[PubMed]
356.
Freedman AS, Takvorian T, Anderson KC.
et al. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse.
J Clin Oncol.
1990; 8: 1–8.
[PubMed]
357.
Peterson FB, Appelbaum FR, Hill R.
et al. Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle.
J Clin Oncol.
1990; 8: 638–47.
[PubMed]
358.
Philip T, Armitage JO, Spitzer G.
et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.
N Engl J Med.
1987; 316: 1493–8.
[PubMed]
359.
Philips GL, Fay JW, Herzig RH.
et al. The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation.
Blood.
1990; 75: 831–8.
[PubMed]
360.
Philip T, Guglielmi C, Chauvin F. et al. Autologus bone marrow transplantation versus conventional chemotherapy (DHAP) in relapsed non-Hodgkin's lymphoma: final analysis of the PARMA randomized study.
Proc ASCO.
1995; 14: 390.
361.
Blay J, Gomez F, Sebban C, Bachelot T.
The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group.
Blood.
1998; 92: 3562–8.
[PubMed]
362.
Sweetenham J, Liberti G, Pearce R.
et al. High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: results of the European Group for Bone Marrow Transplantation.
J Clin Oncol.
1994; 12: 1358–65.
[PubMed]
363.
Sweetenham J, Pearce R, Taghipour G, Blaise D.
Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma—outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation.
J Clin Oncol.
1996; 14: 2465–72.
[PubMed]
364.
Brenner M, Rill D, Moen R.
et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation.
Lancet.
1993; 341: 85–6.
[PubMed]
365.
Deisseroth A, Zu Z, Claxton D.
et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML.
Blood.
1994; 83: 3068–76.
[PubMed]
366.
Schouten HC, Bierman PJ, Vaughan WP.
et al. Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation.
Blood.
1989; 74: 2579–84.
[PubMed]
367.
Freedman AS, Ritz J, Neuberg D.
et al. Autologous bone marrow transplantation in 69 patients with a history of low grade B cell non-Hodgkin's lymphoma.
Blood.
1991; 77: 2524–9.
[PubMed]
368.
Colombat P, Donadio D, Fouillard L.
et al. Value of autologous bone marrow transplantation in follicular lymphoma: a France Autogreffe retrospective study of 42 patients.
Bone Marrow Transplant.
1994; 13: 157–62.
[PubMed]
369.
Rohatiner A, Johnson P, Price C.
et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma.
J Clin Oncol.
1994; 12: 1177–1124.
[PubMed]
370.
Freedman A, Neuberg D, Mauch P.
et al. Long term followup of autologous bone marrow transplantation in patients with relapsed follicular lymphoma.
Blood.
1999; 94: 3325–33.
[PubMed]
371.
Bierman P, Vose J, Anderson J.
et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma.
J Clin Oncol.
1997; 15: 445–50.
[PubMed]
372.
Bastion Y, Brice P, Haioun C.
et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma.
Blood.
1995; 86: 3257–62.
[PubMed]
373.
Foran J, Apostolidis J, Papamichael D.
et al. High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre.
Ann Oncol.
1998; 9: 865–9.
[PubMed]
374.
Freedman A, Takvorian T, Neuberg D.
et al. Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-hodgkin's lymphoma in first remision: a pilot study.
J Clin Oncol.
1993; 11: 931–6.
[PubMed]
375.
Philip T, Hartmann O, Biron P.
et al. High-dose therapy and autologous bone marrow transplantation in partial remission after first-line induction therapy for diffuse non-Hodgkin's lymphoma.
J Clin Oncol.
1988; 6: 1118–24.
[PubMed]
376.
Nademanee A, Schmidt G, O'Donnell M.
et al. High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remissionin adult patients with poor-risk aggressive lymphoma: a pilot study.
Blood.
1992; 80: 1130–4.
[PubMed]
377.
Sweetenham J, Proctor S, Blaise D.
et al. High-dose therapy and autologous bone marrow transplantation in first complete remission for adult patients with high-grade non-Hodgkin's lymphoma: the EBMT experience. Lymphoma Workng Party of the European Group for Bone Marrow Transplantation.
Ann Oncol.
1994; 5 Suppl 2(Suppl 2): 155–9.
[PubMed]
378.
Gianni A, Bregni M, Siena S.
et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma.
N Engl J Med.
1997; 336: 1290–7.
[PubMed]
379.
Verdonck L, Van Putten W, Hagenbeek A.
et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma.
N Engl J Med.
1995; 332: 1045–51.
[PubMed]
380.
Haioun C, Lepage E, Gisselbrecht C.
et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.
J Clin Oncol.
1994; 12: 2543–51.
[PubMed]
381.
Haioun C, Lepage E, Gisselbrecht C.
et al. Autologous bone marrow transplantation versus sequential chemotherapy for aggressive non-Hodgkin's lymphoma in first remission: a study of 542 patients (LNH87-2 protocol) [abstract].
Blood.
1995; 86: 457a. [PubMed]
382.
Santini G, Salvagno L, Leoni P, Chisesi T.
VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the Non-Hodgkin's Lymphoma Cooperative Study Group.
J Clin Oncol.
1998; 16: 2796–802.
[PubMed]
383.
Martelli M, Vignetti M, Zinzani P.
et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethosone, cisplatin and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study.
J Clin Oncol.
1996; 14: 534–9.
[PubMed]
384.
Shipp M, Shulman L, Kaplan W. et al. Intensified induction therapy for patients with “high-risk” aggresive NHL: high dose CHOP [abstract].
Blood.
1993; 82: 332a.
385.
Waters JS, Webb A, Cunningham D.
et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma.
J Clin Oncol.
2000; 18: 1812–23.
[PubMed]
386.
Czuczman M, Grillo-Lopez A, White C.
et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chemeric anti-CD20 monoclonal antibody and CHOP chemotherapy.
J Clin Oncol.
1999; 17: 268–76.
[PubMed]
387.
Kwak L, Campbell M, Czerwinski D.
et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoclobulin idiotype expressed by their tumors.
N Engl J Med.
1992; 327: 1209–15.
[PubMed]
388.
Hsu F, Benike C, Fagnoni F.
et al. Vaccination of patients with B-cell lymphoma using autologous antigen pulsed dendritic cells.
Nature Med.
1996; 2: 52–8.
[PubMed]
389.
Hsu F, Caspar C, Czerwinski D.
et al. Tumor-specific idoitype vaccines in the treatment of patients with B-cell lymphoma- long term-results of a clinical trial.
Blood.
1997; 89: 3129–35.
[PubMed]
390.
Bendandi M, Gocke C, Kobrin C. et al. Molecular complete remissions induced by patient-specific vaccination in most patients with follicular lymphoma [abstract].
Blood.
1998; 92: 153a.
391.
Timmerman JM, Czerwinski DK, Davis TA.
et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
Blood.
2002; 99: 1517–26.
[PubMed]
392.
Bendandi M, Gocke CD, Kobrin CB.
et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.
Nat Med.
1999; 5: 1171–7.
[PubMed] 